TherapeuticsMD Announces Investor and Analyst Day on June 4
BOCA RATON, Fla.--(BUSINESS WIRE)--May 16, 2018--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company will host an Investor and Analyst Day on Monday, June 4, 2018, in New York City.
The event will feature presentations by the TherapeuticsMD senior leadership team and industry experts to provide an overview of the company’s outlook and strategy for its two late-stage women’s health product candidates: TX-004HR for treatment of moderate-to-severe vaginal pain associated with sexual activity (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause, and TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS), due to menopause.
The Prescription Drug User Fee Act (PDUFA) target action date for the completion of the U.S. Food and Drug Administration (FDA) review of the New Drug Application (NDA) for TX-004HR is May 29, 2018 and for TX-001HR is October 28, 2018.
Members of the investment community who would like to attend should register via this link to receive additional registration information.
Additionally, a live webcast of the event will be available on the company’s website, www.therapeuticsmd.com, on the Home Page or under the “Investors & Media” section.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The Company’s late stage clinical pipeline includes two product candidates that have completed phase 3 trials and are awaiting approval by the FDA: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain associated with sexual activity (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. The Company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to resolve the deficiencies identified by the FDA in the company’s new drug application for its TX-004HR product candidate and the time frame associated with such resolution; whether the FDA will approve the amended NDA for the company’s TX-004HR product candidate and whether such approval will occur by the PDUFA target action date; whether the FDA will approve the NDA for the company’s TX-001HR product candidate and whether such approval will occur by the PDUFA target action date; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company be able to comply with the covenants and conditions under its term loan agreement; the length, cost and uncertain results of the company’s clinical trials, including any additional clinical trials that the FDA may require in connection with TX-004HR; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516006269/en/
CONTACT: TherapeuticsMD, Inc.
David DeLucia, 561-961-1900
Director, Investor Relations
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: WOMEN HEALTH PHARMACEUTICAL CONSUMER
SOURCE: TherapeuticsMD, Inc.
Copyright Business Wire 2018.
PUB: 05/16/2018 04:30 PM/DISC: 05/16/2018 04:30 PM